Translational Nanotechnology for Improved Cardiovascular Risk Assessment

Project: Research project

Project Details


Coronary heart disease is the number one killer globally and is responsible for causing heart attacks and angina (heart pain). Although traditional risk factors such as age, smoking status, cholesterol levels, and blood pressure help guide physicians in understanding who is at risk for developing coronary heart disease, there is no crystal ball, and risk prediction remains imperfect. Thus there is great need to develop additional strategies to help predict who is at risk for developing heart disease so that these patients can get more intensive therapies. The investigator for this project has invented a new test called the AuraChol test. This test harnesses the power of gold nanoparticles one tenthousandth the thickness of a human hair to measure how well highdensity lipoprotein (HDL, or "good cholesterol") functions in patients. This new AuraChol test will be compared to the laboratory standard test, the cellular reverse cholesterol transport assay. Unlike the standard test used in research laboratories, the AuraChol test is rapid (4 hour versus 72 hour turnaround), automatable, and does not depend on tissue culture techniques or radiochemicals.
Effective start/end date1/1/1412/31/15


  • Northwestern Memorial Hospital (NMH02052014/Exhibit B.7)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.